Nasal steroids provided the most significant benefit, especially when compared to montelukast. Nasal antihistamines also ...

GSK (GSK) stock in focus as its experimental drug depemokimab undergoes EU review for asthma and nasal polyps. Read more here ...

EMA accepts for review GSK’s MAA for depemokimab for use in asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 09:00 Hrs [IST] GSK plc announced ...

GSK (GSK) announced that the European Medicines Agency, EMA, has accepted for review the Marketing Authorisation Application, MAA, for the use of depemokimab in two indications. The submitted indicati ...

GSK announces depemokimab applications accepted for review in China and Japan for asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 17:00 Hrs [IS ...

GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency has accepted for review the Marketing Authorisation Application for the use of depemokimab in two indications. The submitted ...

In CRS with and without nasal polyps, medical treatment, including nasal and oral corticosteroids, is the first therapeutic option. The treatment of CRS still remains an unmet need ...

London: GSK plc has announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorisation ...

Depemokimab is a follow-up to GSK's Nucala (mepolizumab), a once-monthly IL-5 inhibitor approved for severe asthma, CRSwNP, ...

New NHS treatment gives hope to thousands who suffer from common allergy - The first-of-its-kind tablet will offer relief ...

Objective: Corticosteroids are effective in controlling ... Total symptom scores, nasal obstruction, and doctor and patient perception of improvement were measured as markers of disease severity.

The NHS will now offer immunotherapy pill Acarizax so the body can become less sensitive to dust mites over time and halt ...